Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 56, Issue , 2015, Pages 27-38

  Morin, Nicolas ^a,b   Morissette, Marc ^b   Grégoire, Laurent ^b   Di Paolo, Thérèse ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b University Laval   (Canada)

Author keywords

Basal ganglia; L DOPA induced dyskinesia; MPEP; MPTP monkey; Serotonin receptor; Serotonin transporter

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; CITALOPRAM; LEVODOPA; METABOTROPIC RECEPTOR 5; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; 3-METHOXYTYRAMINE; 6-METHYL-2-(PHENYLETHYNYL)PYRIDINE; AMINO ACID RECEPTOR BLOCKING AGENT; BENSERAZIDE; BENSERAZIDE, LEVODOPA DRUG COMBINATION; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG COMBINATION; HOMOVANILLIC ACID; PROTEIN BINDING; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CAUDATE NUCLEUS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DYSKINESIA; FEMALE; GLOBUS PALLIDUS; IMAGE ANALYSIS; MACACA FASCICULARIS; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PROTEIN BINDING; PUTAMEN; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; DISEASE MODEL; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; METABOLISM; OVARIECTOMY; PARKINSONIAN DISORDERS; PATHOLOGY; PATHOPHYSIOLOGY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BENSERAZIDE; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DYSKINESIA, DRUG-INDUCED; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HOMOVANILLIC ACID; LEVODOPA; MACACA FASCICULARIS; OVARIECTOMY; PARKINSONIAN DISORDERS; PROTEIN BINDING; PYRIDINES; SEROTONIN;

EID: 84905837154     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2014.07.006     Document Type: Article

References (93)

1. Aghajanian G.K., Marek G.J. Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res 1999, 825:161-171.
2. Agid Y., Cervera P., Hirsch E., Javoy-Agid F., Lehericy S., Raisman R., Ruberg M. Biochemistry of Parkinson's disease 28years later: a critical review. Mov Disord 1989, S126-S144. [Suppl. 1].
3. Ansah T.A., Ferguson M.C., Nayyar T. The 5-HT(2A) receptor antagonist M100907 produces antiparkinsonian effects and decreases striatal glutamate. Front Syst Neurosci 2011, 5:48.
4. Antonelli T., Fuxe K., Tomasini M.C., Bartoszyk G.D., Seyfried C.A., Tanganelli S., Ferraro L. Effects of sarizotan on the corticostriatal glutamate pathways. Synapse 2005, 58:193-199.
5. Bara-Jimenez W., Bibbiani F., Morris M.J., Dimitrova T., Sherzai A., Mouradian M.M., Chase T.N. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov Disord 2005, 20:932-936.
6. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38:1083-1152.
7. Bethea C.L., Reddy A.P., Tokuyama Y., Henderson J.A., Lima F.B. Protective actions of ovarian hormones in the serotonin system of macaques. Front Neuroendocrinol 2009, 30:212-238.
8. Bezard E., Tronci E., Pioli E.Y., Li Q., Porras G., Bjorklund A., Carta M. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov Disord 2013, 28:1088-1096.
9. Blanchet P.J., Konitsiotis S., Whittemore E.R., Zhou Z.L., Woodward R.M., Chase T.N. Differing effects of N-methyl-d-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther 1999, 290:1034-1040.
10. Borroto-Escuela D.O., Romero-Fernandez W., Tarakanov A.O., Marcellino D., Ciruela F., Agnati L.F., Fuxe K. Dopamine D2 and 5-hydroxytryptamine 5-HT((2)A) receptors assemble into functionally interacting heteromers. Biochem Biophys Res Commun 2010, 401:605-610.
11. Bryant H.U., Nelson D.L., Button D., Cole H.W., Baez M.B., Lucaites V.L., Wainscott D.B., Whitesitt C., Reel J., Simon R., Koppel G.A. A novel class of 5-HT2A receptor antagonists: aryl aminoguanidines. Life Sci 1996, 59:1259-1268.
12. Calcagno E., Carli M., Invernizzi R.W. The 5-HT(1A) receptor agonist 8-OH-DPAT prevents prefrontocortical glutamate and serotonin release in response to blockade of cortical NMDA receptors. J Neurochem 2006, 96:853-860.
13. Calon F., Morissette M., Rajput A.H., Hornykiewicz O., Bedard P.J., Di Paolo T. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov Disord 2003, 18:241-253.
14. Carta M., Carlsson T., Kirik D., Bjorklund A. Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007, 130:1819-1833.
15. Carta M., Carlsson T., Munoz A., Kirik D., Bjorklund A. Serotonin-dopamine interaction in the induction and maintenance of l-DOPA-induced dyskinesias. Prog Brain Res 2008, 172:465-478.
16. Cash R., Raisman R., Ploska A., Agid Y. High and low affinity [3H]imipramine binding sites in control and parkinsonian brains. Eur J Pharmacol 1985, 117:71-80.
17. Chase T.N., Oh J.D. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol 2000, 47:S122-S129. [discussion S129-130].
18. Chinaglia G., Landwehrmeyer B., Probst A., Palacios J.M. Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram. Neuroscience 1993, 54:691-699.
19. Cyr M., Bosse R., Di Paolo T. Gonadal hormones modulate 5-hydroxytryptamine 2A receptors: emphasis on the rat frontal cortex. Neuroscience 1998, 83:829-836.
20. Darchen F., Scherman D., Laduron P.M., Henry J.P. Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles. Mol Pharmacol 1988, 33:672-677.
21. Dekundy A., Pietraszek M., Schaefer D., Cenci M.A., Danysz W. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Res Bull 2006, 69:318-326.
22. Dupre K.B., Ostock C.Y., Eskow Jaunarajs K.L., Button T., Savage L.M., Wolf W., Bishop C. Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. Exp Neurol 2011, 229:288-299.
23. Fabbrini G., Brotchie J.M., Grandas F., Nomoto M., Goetz C.G. Levodopa-induced dyskinesias. Mov Disord 2007, 22:1379-1389.
24. Farber N.B., Hanslick J., Kirby C., McWilliams L., Olney J.W. Serotonergic agents that activate 5HT2A receptors prevent NMDA antagonist neurotoxicity. Neuropsychopharmacology 1998, 18:57-62.
25. Fox S.H., Chuang R., Brotchie J.M. Serotonin and Parkinson's disease: on movement, mood, and madness. Mov Disord 2009, 24:1255-1266.
26. Frechilla D., Cobreros A., Saldise L., Moratalla R., Insausti R., Luquin M., Del Rio J. Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 2001, 39:288-296.
27. Goulet M., Morissette M., Grondin R., Falardeau P., Bedard P.J., Rostene W., Di Paolo T. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys. Synapse 1999, 32:153-164.
28. Gravius A., Dekundy A., Nagel J., More L., Pietraszek M., Danysz W. Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats. J Neural Transm 2008, 115:1609-1619.
29. Gregoire L., Samadi P., Graham J., Bedard P.J., Bartoszyk G.D., Di Paolo T. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-Dopa in parkinsonian monkeys. Parkinsonism Relat Disord 2009, 15:445-452.
30. Hornykiewicz O. Brain monoamines and parkinsonism. Natl Inst Drug Abuse Res Monogr Ser 1975, 13-21.
31. Huot P., Fox S.H., Brotchie J.M. The serotonergic system in Parkinson's disease. Prog Neurobiol 2011, 95:163-212.
32. Huot P., Johnston T.H., Koprich J.B., Winkelmolen L., Fox S.H., Brotchie J.M. Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque. Neurobiol Aging 2012, 33(207):e209-e219.
33. Huot P., Johnston T.H., Winkelmolen L., Fox S.H., Brotchie J.M. 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with l-DOPA. Neurobiol Aging 2012, 33(115):e194-e195.
34. Huot P., Johnston T.H., Koprich J.B., Fox S.H., Brotchie J.M. The pharmacology of l-DOPA-induced dyskinesia in Parkinson's disease. Pharmacol Rev 2013, 65:171-222.
35. Iravani M.M., Tayarani-Binazir K., Chu W.B., Jackson M.J., Jenner P. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability. J Pharmacol Exp Ther 2006, 319:1225-1234.
36. Ismaiel A.M., Arruda K., Teitler M., Glennon R.A. Ketanserin analogues: the effect of structural modification on 5-HT2 serotonin receptor binding. J Med Chem 1995, 38:1196-1202.
37. Jenner P. Molecular mechanisms of l-DOPA-induced dyskinesia. Nat Rev Neurosci 2008, 9:665-677.
38. Kannari K., Yamato H., Shen H., Tomiyama M., Suda T., Matsunaga M. Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered l-DOPA in the striatum with nigrostriatal denervation. J Neurochem 2001, 76:1346-1353.
39. Kerenyi L., Ricaurte G.A., Schretlen D.J., McCann U., Varga J., Mathews W.B., Ravert H.T., Dannals R.F., Hilton J., Wong D.F., Szabo Z. Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol 2003, 60:1223-1229.
40. Kish S.J., Tong J., Hornykiewicz O., Rajput A., Chang L.J., Guttman M., Furukawa Y. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008, 131:120-131.
41. Lejeune F., Newman-Tancredi A., Audinot V., Millan M.J. Interactions of (+)- and (-)-8- and 7-hydroxy-2-(di-n-propylamino)tetralin at human (h)D3, hD2 and h serotonin1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurons in rats. J Pharmacol Exp Ther 1997, 280:1241-1249.
42. Levandis G., Bazzini E., Armentero M.T., Nappi G., Blandini F. Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neurobiol Dis 2008, 29:161-168.
43. Li Z., Ichikawa J., Dai J., Meltzer H.Y. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 2004, 493:75-83.
44. Lindgren H.S., Andersson D.R., Lagerkvist S., Nissbrandt H., Cenci M.A. l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J Neurochem 2010, 112:1465-1476.
45. Lucas G., Spampinato U. Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J Neurochem 2000, 74:693-701.
46. Lukasiewicz S., Polit A., Kedracka-Krok S., Wedzony K., Mackowiak M., Dziedzicka-Wasylewska M. Hetero-dimerization of serotonin 5-HT(2A) and dopamine D(2) receptors. Biochim Biophys Acta 2010, 1803:1347-1358.
47. Maeda T., Nagata K., Yoshida Y., Kannari K. Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA. Brain Res 2005, 1046:230-233.
48. Mauler F., Fahrig T., Horvath E., Jork R. Inhibition of evoked glutamate release by the neuroprotective 5-HT(1A) receptor agonist BAY x 3702 in vitro and in vivo. Brain Res 2001, 888:150-157.
49. Meco G., Stirpe P., Edito F., Purcaro C., Valente M., Bernardi S., Vanacore N. Aripiprazole in l-dopa-induced dyskinesias: a one-year open-label pilot study. J Neural Transm 2009, 116:881-884.
50. Mela F., Marti M., Dekundy A., Danysz W., Morari M., Cenci M.A. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J Neurochem 2007, 101:483-497.
51. Mercuri N.B., Bernardi G. The 'magic' of l-dopa: why is it the gold standard Parkinson's disease therapy?. Trends Pharmacol Sci 2005, 26:341-344.
52. Morin N., Gregoire L., Morissette M., Desrayaud S., Gomez-Mancilla B., Gasparini F., Di Paolo T. MPEP, an mGlu5 receptor antagonist, reduces the development of l-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates. Neuropharmacology 2013, 66:355-364.
53. Morin N., Morissette M., Gregoire L., Gomez-Mancilla B., Gasparini F., Di Paolo T. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in l-DOPA-treated parkinsonian monkeys. Neuropharmacology 2013, 73:216-231.
54. Morin N., Jourdain V.A., Di Paolo T. Modeling dyskinesia in animal models of Parkinson disease. Exp Neurol 2014, 256:105-116.
55. Morin N., Jourdain V.A., Morissette M., Gregoire L., Di Paolo T. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys. Neuropharmacology 2014, 79:688-706.
56. Morissette M., Dridi M., Calon F., Hadj Tahar A., Meltzer L.T., Bedard P.J., Di Paolo T. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-d-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin. Mov Disord 2006, 21:9-17.
57. Murthy V., Martin T.J., Kim S., Davies H.M., Childers S.R. In vivo characterization of a novel phenylisothiocyanate tropane analog at monoamine transporters in rat brain. J Pharmacol Exp Ther 2008, 326:587-595.
58. Navailles S., De Deurwaerdere P. Imbalanced dopaminergic transmission mediated by serotonergic neurons in l-DOPA-induced dyskinesia. Parkinson's disease 2012 2012, 1-16.
59. 2+ mobilizing agents mimic serotonin 5-HT2A facilitation of N-methyl-d-aspartate depolarization. Behav Brain Res 1996, 73:273-275.
60. Oh J.D., Bibbiani F., Chase T.N. Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Exp Neurol 2002, 177:557-564.
61. Olijslagers J.E., Werkman T.R., McCreary A.C., Siarey R., Kruse C.G., Wadman W.J. 5-HT2 receptors differentially modulate dopamine-mediated auto-inhibition in A9 and A10 midbrain areas of the rat. Neuropharmacology 2004, 46:504-510.
62. Ouattara B., Belkhir S., Morissette M., Dridi M., Samadi P., Gregoire L., Meltzer L.T., Di Paolo T. Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias. J Mol Neurosci 2009, 38:128-142.
63. Ouattara B., Hoyer D., Gregoire L., Morissette M., Gasparini F., Gomez-Mancilla B., Di Paolo T. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias. Neuroscience 2010, 167:1160-1167.
64. Ouattara B., Gregoire L., Morissette M., Gasparini F., Vranesic I., Bilbe G., Johns D.R., Rajput A., Hornykiewicz O., Rajput A.H., Gomez-Mancilla B., Di Paolo T. Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiol Aging 2011, 32:1286-1295.
65. Paquette M.A., Martinez A.A., Macheda T., Meshul C.K., Johnson S.W., Berger S.P., Giuffrida A. Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors. Eur J Neurosci 2012, 36:3224-3234.
66. Parent A., Hazrati L.N. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev 1995, 20:91-127.
67. Pehek E.A., Nocjar C., Roth B.L., Byrd T.A., Mabrouk O.S. Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex. Neuropsychopharmacology 2006, 31:265-277.
68. Porras G., Di Matteo V., Fracasso C., Lucas G., De Deurwaerdere P., Caccia S., Esposito E., Spampinato U. 5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 2002, 26:311-324.
69. Rahman S., Neuman R.S. Activation of 5-HT2 receptors facilitates depolarization of neocortical neurons by N-methyl-d-aspartate. Eur J Pharmacol 1993, 231:347-354.
70. Ramamoorthy S., Blakely R.D. Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science 1999, 285:763-766.
71. Rascol O., Fox S., Gasparini F., Kenney C., Di Paolo T., Gomez-Mancilla B. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism Relat Disord 2014, [Epub ahead of print]. 10.1016/j.parkreldis.2014.05.003.
72. Riahi G., Morissette M., Parent M., Di Paolo T. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias. Eur J Neurosci 2011, 33:1823-1831.
73. Riahi G., Morissette M., Levesque D., Rouillard C., Samadi P., Parent M., Di Paolo T. Effect of chronic l-DOPA treatment on 5-HT(1A) receptors in parkinsonian monkey brain. Neurochem Int 2012, 61:1160-1171.
74. Rinne U.K., Koskinen V., Lonnberg P. Neurotransmitter receptors in the parkinsonian brain. Parkinson's disease: current progress 1980, 93-107. Problems and Management. Elsevier, North Holland, Amsterdam. U.K. Rinne, M. Klinger, G. Stamm (Eds.).
75. Roberts C. ACP-103, a 5-HT2A receptor inverse agonist. Curr Opin Investig Drugs 2006, 7:653-660.
76. Rodriguez J.J., Garcia D.R., Pickel V.M. Subcellular distribution of 5-hydroxytryptamine2A and N-methyl-d-aspartate receptors within single neurons in rat motor and limbic striatum. J Comp Neurol 1999, 413:219-231.
77. Roselli F., Pisciotta N.M., Pennelli M., Aniello M.S., Gigante A., De Caro M.F., Ferrannini E., Tartaglione B., Niccoli-Asabella A., Defazio G., Livrea P., Rubini G. Midbrain SERT in degenerative parkinsonisms: a 123I-FP-CIT SPECT study. Mov Disord 2010, 25:1853-1859.
78. Rylander D., Parent M., O'Sullivan S.S., Dovero S., Lees A.J., Bezard E., Descarries L., Cenci M.A. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol 2010, 68:619-628.
79. Samadi P., Rouillard C., Bedard P.J., Di Paolo T. Functional neurochemistry of the basal ganglia. Handb Clin Neurol 2007, 83:19-66.
80. Samadi P., Gregoire L., Morissette M., Calon F., Hadj Tahar A., Dridi M., Belanger N., Meltzer L.T., Bedard P.J., Di Paolo T. mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol Aging 2008, 29:1040-1051.
81. Sanchez M.G., Estrada-Camarena E., Belanger N., Morissette M., Di Paolo T. Estradiol modulation of cortical, striatal and raphe nucleus 5-HT1A and 5-HT2A receptors of female hemiparkinsonian monkeys after long-term ovariectomy. Neuropharmacology 2011, 60:642-652.
82. Sanchez M.G., Morissette M., Di Paolo T. Estradiol and brain serotonin reuptake transporter in long-term ovariectomized parkinsonian monkeys. Prog Neuropsychopharmacol Biol Psychiatry 2013, 45:170-177.
83. Schmidt C.J., Sullivan C.K., Fadayel G.M. Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J Neurochem 1994, 62:1382-1389.
84. Sprouse J.S., Aghajanian G.K. Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists. Synapse 1987, 1:3-9.
85. Sprouse J.S., Aghajanian G.K. Responses of hippocampal pyramidal cells to putative serotonin 5-HT1A and 5-HT1B agonists: a comparative study with dorsal raphe neurons. Neuropharmacology 1988, 27:707-715.
86. Stocchi F., Rascol O., Destee A., Hattori N., Hauser R.A., Lang A.E., Poewe W., Stacy M., Tolosa E., Gao H., Nagel J., Merschhemke M., Graf A., Kenney C., Trenkwalder C. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord 2013, 28:1838-1846.
87. Stockmeier C.A., Shapiro L.A., Haycock J.W., Thompson P.A., Lowy M.T. Quantitative subregional distribution of serotonin1A receptors and serotonin transporters in the human dorsal raphe. Brain Res 1996, 727:1-12.
88. Suwijn S.R., Berendse H.W., Verschuur C.V., Winogrodzka A., de Bie R.M., Booij J. SERT-to-DAT ratios in early Parkinson's disease do not correlate with the development of dyskinesias. EJNMMI Res 2013, 3:44.
89. Szabo J., Cowan W.M. A stereotaxic atlas of the brain of the cynomolgus monkey (Macaca fascicularis). J Comp Neurol 1984, 222:265-300.
90. Addex Therapeutics Geneva, Switzerland [media release]. 2012 Mar 21 [online]. Available from, [Accessed 2014 Feb 11]. http://www.addextherapeutics.com/investors/press-releases/news-details/article/addex-reports-positive-top-line-phase-iia-data-for-dipraglurant-in-parkinsons-disease-levodopa-indu/.
91. Verhagen Metman L., Del Dotto P., van den Munckhof P., Fang J., Mouradian M.M., Chase T.N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998, 50:1323-1326.
92. Wang J.L., Oya S., Parhi A.K., Lieberman B.P., Ploessl K., Hou C., Kung H.F. In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease. Nucl Med Biol 2010, 37:479-486.
93. Wood M., Chaubey M., Atkinson P., Thomas D.R. Antagonist activity of meta-chlorophenylpiperazine and partial agonist activity of 8-OH-DPAT at the 5-HT(7) receptor. Eur J Pharmacol 2000, 396:1-8.